Trials / Enrolling By Invitation

Enrolling By InvitationNCT07122882

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Integrated Genomics in Oncogene-driven Non-small Cell Lung Cancer With Acquired Resistance to Tyrosine Kinase Inhibitors

Status: Enrolling By Invitation
Phase: —
Study type: Observational
Enrollment: 40 (estimated)

Sponsor: Chang Gung Memorial Hospital · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resistance against TKI in clinical practice. Therefore, understanding the molecular mechanisms underlying the acquired resistance is a critical issue in lung cancer. Based on the literature, acquired resistance mechanism against EGFR TKI includes EGFR secondary mutation (T790M, C797X, L792X, G796X, L718Q, and exon 20 insertions), MET amplification, HER2 amplification, acquired gene fusions, and other complex alterations. From the perspective of mutagenesis, the acquired resistance against TKI may be associated with APOBEC mutational processes, kataegis, chromothripsis, extrachromosomal DNA (ecDNA), and the interaction among them. However, still 30% to 50% of oncogene-driven NSCLCs had no identified mechanism attributed to the acquired resistance. Previous studies mostly used targeted-gene sequencing, which may overlook some structural variation and the transcriptomic dynamics. This study aims to investigate the genomic alterations, mutational processes, and the transcriptomic landscape underlying the acquired resistance using integrated genomics.

Conditions

Timeline

Start date: 2025-09-01
Primary completion: 2027-05-11
Completion: 2028-05-11
First posted: 2025-08-14
Last updated: 2026-03-17

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT07122882. Inclusion in this directory is not an endorsement.